Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer
April 09 2018 - 7:00AM
Immunomedics, Inc., (NASDAQ:IMMU)
(“Immunomedics” or the “Company”), a leader in the field of
antibody-drug conjugates (ADCs), today announced the appointment of
Robert Iannone, M.D., M.S.C.E., as Head of Research &
Development and Chief Medical Officer, effective today. In his new
role, Dr. Iannone will oversee and lead all clinical development,
regulatory, pre-clinical, translational research and medical
affairs strategies and activities of the Company. Dr. Iannone
brings more than thirteen years of experience in clinical drug
development, including the approval of several targeted and
immuno-oncology medicines at AstraZeneca/MedImmune and Merck &
Co.
“Rob is not only a highly accomplished oncology
drug developer but also is deeply rooted in science with
outstanding development experience and an established track record
in a number of disease settings of interest to Immunomedics. We are
thrilled that Rob is bringing his strong industry, medical,
scientific and strategic leadership to Immunomedics,” commented
Michael Pehl, President and Chief Executive Officer. “Through his
unique expertise, Rob will be instrumental in aggressively
advancing development of our programs with the right drug
combinations and in the most appropriate patient segments. I look
forward to working closely with Rob to unlock the full potential of
our ADC platform and further strengthen Immunomedics as a leader in
this field.”
Dr. Iannone comes to Immunomedics from
AstraZeneca/MedImmune where he oversaw the development of Imfinzi
and was, most recently, Senior Vice President and Head of
Immuno-oncology, Global Medicines Development. He joined
AstraZeneca/MedImmune in July 2014 as Global Products Vice
President. Prior to AstraZeneca/MedImmune, Dr. Iannone served as
Executive Director, Clinical Research, and Section Head of Oncology
at Merck Research Laboratories and was a development leader for
Keytruda®.
“Immunomedics has a unique and highly
differentiated ADC pipeline and platform technology. I am very
excited to be joining the Company to help develop sacituzumab
govitecan and other pipeline assets, to be foundational therapies
in a wide variety of hard-to-treat solid cancer indications, in
both early- and late-line settings, including the potential for
combining with immune checkpoint inhibitors and other targeted
cancer therapies,” remarked Dr. Iannone.
Dr. Iannone received his M.D. from Yale
University School of Medicine with Alpha Omega Alpha honors and a
Master of Science in Clinical Epidemiology from the University of
Pennsylvania School of Medicine. Dr. Iannone completed his
Residency at Johns Hopkins Hospital, where he also served as Chief
Resident for one year and completed his Pediatric Hematology and
Oncology Fellowship. Dr Iannone is the author or co-author of
numerous articles in peer-reviewed journals and has served on the
Biomarkers Consortium of the Cancer Steering Committee of the
Foundation for the National Institutes of Health since 2011.
About ImmunomedicsImmunomedics
is a clinical-stage biopharmaceutical company developing monoclonal
antibody-based products for the targeted treatment of cancer and
other serious diseases. Immunomedics’ corporate objective is to
become a fully-integrated biopharmaceutical company and a leader in
the field of antibody-drug conjugates. To that end, Immunomedics’
immediate priority is to commercialize its most advanced product
candidate, sacituzumab govitecan (IMMU-132), beginning in the U.S.,
with metastatic triple-negative breast cancer as the first
indication. For additional information on the Company, please visit
its website at https://immunomedics.com/. The information on its
website does not, however, form a part of this press release.
Cautionary note regarding
forward-looking statementsThis release, in addition to
historical information, may contain forward-looking statements made
pursuant to the Private Securities Litigation Reform Act of 1995.
Such statements, including statements regarding clinical trials
(including the funding therefor, anticipated patient enrollment,
trial outcomes, timing or associated costs), regulatory
applications and related timelines, including the anticipated
filing timeline for the BLA, out-licensing arrangements, forecasts
of future operating results, potential collaborations, and capital
raising activities, timing for bringing any product candidate to
market, involve significant risks and uncertainties and actual
results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are
not limited to, the Company’s dependence on business collaborations
or availability of required financing from capital markets, or
other sources on acceptable terms, if at all, in order to further
develop our products and finance our operations, new product
development (including clinical trials outcome and regulatory
requirements/actions), the risk that we or any of our collaborators
may be unable to secure regulatory approval of and market our drug
candidates, risks associated with the outcome of pending litigation
and competitive risks to marketed products, and the Company’s
ability to repay its outstanding indebtedness, if and when
required, as well as the risks discussed in the Company’s filings
with the Securities and Exchange Commission. The Company is
not under any obligation, and the Company expressly disclaims any
obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or
otherwise.
For More
Information:Dr. Chau ChengSenior
Director, Investor Relations & Corporate Secretary(973)
605-8200, extension 123ccheng@immunomedics.com
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2024 to May 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From May 2023 to May 2024